YOUR ADOLESCENT AND YOUNG ADULT PATIENTS MAY BE AT AN INCREASED RISK FOR MenB¹

Between 2011 and December 2017, 7 cases of serogroup B meningococcal disease (MenB) occurred at universities in Pennsylvania.²⁻⁶

BUCKNELL UNIVERSITY:

2 cases in 1 month

1 case (confirmed) - November 2017 1 case (presumed) - November 2017 As of January 2018, all incoming undergraduate and graduate students are required to have at least 1 dose of a MenB vaccine.⁷

LEHIGH UNIVERSITY:

2 cases - November 2011 Both survived

All incoming students are required to have completed the MenB vaccine series.⁸

KUTZTOWN UNIVERSITY:


2 cases

1 case - May 2014 1 case - December 2017 **Both survived**

DREXEL UNIVERSITY:

1 case - March 2014

Death



PENNSYLVANIA



MenB is an uncommon, but serious disease that can attack without warning and potentially lead to long-term permanent disability or disfigurement in survivors or even death within 24 hours.^{9,10}



MenB is spread through typical adolescent and young adult behaviors such as living in close quarters; sharing drinks, cups, or utensils; and kissing.¹¹



MenB accounts for approximately 60% of all meningococcal disease cases in persons aged 16 through 23 years of age in the United States.¹²

*Includes nongroupables



MenB has been responsible for all US college outbreaks of meningococcal disease between 2011 and 2016.^{13†}


 $^{+}$ Until 2014, available MCV4 vaccines only protected against 4 (A, C, W, Y) of the 5 primary serogroups (which also includes serogroup B).

HELP PROTECT YOUR ADOLESCENT AND YOUNG ADULT PATIENTS WITH A VACCINATION FOR MenB

Advisory Committee on Immunization Practices (ACIP) Recommendations for MenB Vaccinations¹⁴

- **Category A:** ACIP recommends MenB vaccination for persons aged ≥10 years who are in a MenB outbreak situation or at increased risk for meningococcal disease
- **Category B:** ACIP recommends that MenB vaccination may be administered to healthy adolescents and young adults, aged 16 through 23 years, who are not at increased risk for meningococcal disease to provide short-term protection against most strains of MenB

The preferred age for MenB vaccination is 16 through 18 years.¹⁴



Among 10- through 25-year-olds, the incidence of MenB peaks around 19 years of age.¹



References: 1. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses. http://www.nfid.org/ idinfo/meningococcal/meningococcal-b-outbreaks.pdf. Accessed November 14, 2017. 2. Data on file. Pfizer Inc, New York, NY. 3. Kutztown University; Berks-Mont News. Kutztown University student hospitalized with Meningitis B. Berks-Mont News website. http://www.berksmontnews.com/article/BM/20171220/NEWS/171229994. Updated December 21, 2017, Accessed May 15, 2018, 4, The Bucknellian, Two students hospitalized for meningitis over holiday break. The Bucknellian website, https://bucknellian. net/80931/news/two-students-hospitalized-meningitis-holiday-break/. Published November 30, 2017. Accessed May 14, 2018. 5. National Meningitis Association. NMA Advocates in Pennsylvania: Beverly and Steve Ross, Pennsylvania; Parents of Stephanie (Age 19). National Meningitis Association website. http://www.nmaus.org/stories/nmaadvocates/pennsylvania/. Accessed May 15, 2018. 6. Lehigh University Student Affairs. Meningococcal information form, 2015. Lehigh University website. https://studentaffairs. lehigh.edu/sites/studentaffairs.lehigh.edu/files/offices/health/docs/2015MeningitisInfoForm2015.pdf. Accessed May 14, 2018. 7. Bucknell University. Student Health medical forms. Bucknell University website. https://www.bucknell.edu/Documents/HealthServices/MedicalRecordForm.pdf. Accessed May 15, 2018. 8. Lehigh University Health & Wellness Center. Student Health Medical Forms. Bethlehem, PA: Lehigh University; 2017. 9. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25. 10. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 11. US Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2016. Centers for Disease Control and Prevention website. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf. Accessed December 1, 2017. 12. US Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated July 6, 2017. Accessed November 14, 2017. 13. Biswas HH, Han GS, Wendorf K, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a university-California, 2016. MMWR. 2016;65(20):520-521. 14. Patton ME, Stephens D, Moore K, et al; Centers for Disease Control and Prevention. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—Advisory Committee on Immunization Practices, 2016. MMWR. 2017;66(19):509-513. 15. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-childcombined-schedule.pdf. Accessed May 31, 2018. 16. American Academy of Pediatrics. Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. American Academy of Pediatrics website. http://pediatrics.aappublications.org/content/pediatrics/138/3/e20161890.full.pdf. Accessed October 24, 2017.

